Becton, Dickinson and Company ("BD") has announced the completion of its spin-off of the Biosciences and Diagnostic Solutions business, which has been combined with Waters Corporation. This significant corporate restructuring is aimed at enhancing BD's focus on its core operations. The company has provided recast historical financial information as Exhibit 99.1 in its recent 8-K filing, which reflects the former business as discontinued operations. This adjustment is intended to give investors a clearer view of BD's standalone operating results. The financial measures presented differ from those under U.S. GAAP, as they include non-GAAP measures that adjust for various costs associated with the spin-off and other operational changes. BD management believes these adjustments will help investors better understand the company's performance and future prospects. The filing also emphasizes that the information provided should not be considered 'filed' under the Securities Exchange Act, nor incorporated by reference into other filings. This strategic move is expected to have a small positive effect on BD's stock price as it aligns the company more closely with its operational goals and market expectations.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.